Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation

Cancer

Volumn 118, Issue 9, 2012, Pages 2411-2419

  Fang, Min ^a,b,c   Storer, Barry ^a   Wood, Brent ^b,c   Gyurkocza, Boglarka ^a,c   Sandmaier, Brenda M ^a,c   Appelbaum, Frederick R ^a,b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

acute myeloid leukemia; cytogenetics; fluorescence in situ hybridization; multicolor flow cytometry

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METAPHASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REMISSION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CYTOGENETICS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RECURRENCE; TREATMENT OUTCOME;

EID: 84860219002     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26539     Document Type: Article

References (21)

1. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96: 4075-4083.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 2322-2333.
3. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115: 453-474.
4. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336.
5. Marcucci G, Mrozek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B Study 8461. J Clin Oncol. 2004; 22: 2410-2418.
6. Freireich EJ, Cork A, Stass SA, et al. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia. 1992; 6: 500-506.
7. Frohling S, Skelin S, Liebisch C, et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 2002; 20: 2480-2485.
8. Wood BL,. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med. 2007; 27: 551-575.
9. Wood B,. Nine-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med. 2006; 130: 680-690.
10. San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001; 98: 1746-1751.
11. Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T,. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica. 2004; 89: 528-540.
12. Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol. 2008; 26: 4944-4951.
13. Appelbaum FR,. Molecular diagnosis and clinical decisions in adult acute leukemia. Semin Hematol. 1999; 36: 401-410.
14. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996; 87: 4789-4796.
15. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995; 85: 2632-2638.
16. Shaffer LG, Slovak ML, Campbell LJ, eds. An International System for Human Cytogenetic Nomenclature. Unionville, CT: S. Karger Publishers, Inc.; 2009.
17. Shaffer LG, Tommerup N,. An International System for Human Cytogenetic Nomenclature. Unionville, CT: S. Karger Publishers, Inc, 2005.
18. Wood BL,. Ten-color immunophenotyping of hematopoietic cells [serial online]. Curr Protoc Cytom. 2005;Chapter 6:Unit 6.21.
19. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011; 29: 1190-1197.
20. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990; 75: 555-562.
21. Bacher U, Kern W, Schoch C, Schnittger S, Hiddemann W, Haferlach T,. Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer. 2006; 106: 839-847.